Cargando...
Metformin Inhibits the Growth of Human Pancreatic Cancer Xenografts
OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease, with overall 5-year survival rate of only 3-5%. As the current therapies offer very limited survival benefits, novel therapeutic strategies are urgently required to treat this disease. Here, we determined whether metformin...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2013
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3681894/ https://ncbi.nlm.nih.gov/pubmed/23462329 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MPA.0b013e31827aec40 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|